Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: A randomized controlled trial

Journal of Chinese Integrative Medicine

Volumn 6, Issue 2, 2008, Pages 134-138

  Zhang, Zhu Yi ^a   Yu, Shi Qing ^b   Miao, Li Yun ^b   Huang, Xiao Ying ^b   Zhang, Xiao Ping ^b   Zhu, Yu Ping ^b   Xia, Xiao Hong ^b   Li, Dan Qi ^b  

^a Department of Respiratory Medicine   (China)

^b Nantong Rich Hospital   (China)

Author keywords

Antineoplastic combined chemotherapy protocols; Antineoplastic drugs (TCD); Non small cell lung carcinoma; Randomized controlled trial

Indexed keywords

ARTESUNATE; CISPLATIN; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE CONTROL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARTEMISININS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; VINBLASTINE;

EID: 39149087695     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jcim20080206     Document Type: Article

References (15)

1. Liu JL, Zheng ZY, Yu RX. Mechanisms of antitumor activities of artemisinin and its derivatives. Zhong Yao Xin Yao Yu Lin Chuang Yao Li. 2006; 17 (2): 155-157.
2. Efferth T, Sauerbrey A, Olbrich A. et al. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol. 2003; 64(2): 382-394.
3. Sadava D, Phillips T, Lin C, et al. Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett. 2002; 179(2): 151-156.
4. Efferth T, Volm M. Glutathione-related enzymes contribute to resistance of tumor cells and low toxicity in normal organs to artesunate. In Vivo. 2005; 19(1): 225-232.
5. Lu CY, Chen XY, Tang BH. A Study in effect of artemisinin and its derivatives on reversion of multi-drug resistance of tumors. Zhongguo Zhong Yi Yao Xin Xi Za Zhi. 2006; 13(4): 12-14.
6. Balint GA. Artemisinin and its derivatives: an important new class of antimalarial agents. Pharmacol Ther. 2001; 90(2-3): 261-265.
7. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3): 205-216.
8. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981; 47(1): 207-14.
9. Miao LY, Zhang ZY. Reversal effect of artesunate on the multidrug-resistance of human leukemia K562/A02 cells. Dong Nan Da Xue Xue Bao (Yi Xue Ban). 2006; 25(6): 445-447.
10. Miao LY, Zhang ZY. The possible mechanism of artesunate's selective cytotoxicity toward human lung adenocarcinoma cells. Xian Dai Yi Xue. 2006; 34(1): 15-17.
11. Chen WQ, Qi HW, Wu CG. Effect of dihydroartemisinin on the proliferation of human lung adenocarcinoma cell line A549 in vitro. Zhongguo Xin Yi Yao. 2004; 3 (5): 9-10.
12. Chen WQ, Qi HW, Wu CG, et al. Inhibition of growth on the human lung adenocarcinoma cell line A549 and A549/CDDP in vitro by dihydroartemisinin in combination with cisplatin. Xian Dai Zhong Liu Yi Xue. 2006; 14(3): 284-286.
13. Di Leo A, Bleiberg H, Buyse M. Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol. 2003; 21(10): 2045-2047.
14. Singh NP, Lai H. Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci. 2001; 70(1): 49-56.
15. Efferth T, Benakis A, Romero MR, et al. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med. 2004; 37(7): 998-1009.